Clinical trial
A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).
NCT06441331 is registered in ClinicalTrials.gov with ITM Solucin GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).
- Lead sponsor
- ITM Solucin GmbH
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 26, 2025
- Completion date
- April 30, 2034
- Enrollment
- 20 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
cns tumors, gist, lymphoma, nets, peripheral primitive neuroectodermal tumor, rhabdomyosarcoma, solid tumor, somatostatin receptor positive